Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520643 | 0.75 | ALDH1A1 (0.48) | MEN1KMT2AMAPTPOLB | |
| SCHEMBL3523595 | 0.72 | ALDH1A1 (0.42) | MEN1KMT2APOLBHPGD | |
| SCHEMBL3523394 | 0.70 | SMN1; SMN2 (0.52) | MEN1KMT2AMAPTTDP1POLB | |
| SCHEMBL3525261 | 0.69 | P2RX4 (0.42) | MEN1KMT2APOLBHPGDCYP2C19 | |
| SCHEMBL3518228 | 0.68 | CYP3A4 (0.45) | CYP2C19 | |
| SCHEMBL3527717 | 0.68 | KDR (0.45) | MEN1KMT2AMAPTXBP1TRPV1 | |
| SCHEMBL11372972 | 0.68 | RAB9A (0.57) | MEN1KMT2AMAPTXBP1NPC1 | |
| SCHEMBL6003943 | 0.65 | TP53 (0.53) | MEN1KMT2AMAPTXBP1NPC1 | |
| SCHEMBL12655774 | 0.63 | ACHE (0.75) | MAPTEPHX2 | |
| SCHEMBL1945608 | 0.63 | EPHX2 (0.67) | MEN1KMT2AMAPTXBP1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MEN1 3915/4885KMT2A 3940/4885MAPT 2576/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MEN1 4074/4885KMT2A 4243/4885MAPT 3038/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MEN1 3915/4885KMT2A 3940/4885MAPT 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.